S&P 500   3,574.85 (+0.49%)
DOW   29,496.73 (+0.80%)
QQQ   290.39 (+0.00%)
AAPL   115.45 (-1.61%)
MSFT   209.88 (-0.24%)
FB   266.59 (-1.15%)
GOOGL   1,727.87 (-0.49%)
AMZN   3,092.90 (-0.21%)
TSLA   524.41 (+7.11%)
NVDA   525.72 (+0.42%)
BABA   270.13 (-0.23%)
CGC   24.08 (+1.52%)
GE   10.24 (+4.92%)
MU   64.13 (+4.45%)
AMD   87.03 (+2.82%)
T   28.52 (+0.71%)
NIO   52.14 (+5.87%)
F   8.91 (+1.95%)
ACB   7.17 (+0.56%)
GILD   59.91 (-0.33%)
NFLX   483.39 (-0.99%)
BA   208.85 (+4.62%)
DIS   142.68 (+1.14%)
S&P 500   3,574.85 (+0.49%)
DOW   29,496.73 (+0.80%)
QQQ   290.39 (+0.00%)
AAPL   115.45 (-1.61%)
MSFT   209.88 (-0.24%)
FB   266.59 (-1.15%)
GOOGL   1,727.87 (-0.49%)
AMZN   3,092.90 (-0.21%)
TSLA   524.41 (+7.11%)
NVDA   525.72 (+0.42%)
BABA   270.13 (-0.23%)
CGC   24.08 (+1.52%)
GE   10.24 (+4.92%)
MU   64.13 (+4.45%)
AMD   87.03 (+2.82%)
T   28.52 (+0.71%)
NIO   52.14 (+5.87%)
F   8.91 (+1.95%)
ACB   7.17 (+0.56%)
GILD   59.91 (-0.33%)
NFLX   483.39 (-0.99%)
BA   208.85 (+4.62%)
DIS   142.68 (+1.14%)
S&P 500   3,574.85 (+0.49%)
DOW   29,496.73 (+0.80%)
QQQ   290.39 (+0.00%)
AAPL   115.45 (-1.61%)
MSFT   209.88 (-0.24%)
FB   266.59 (-1.15%)
GOOGL   1,727.87 (-0.49%)
AMZN   3,092.90 (-0.21%)
TSLA   524.41 (+7.11%)
NVDA   525.72 (+0.42%)
BABA   270.13 (-0.23%)
CGC   24.08 (+1.52%)
GE   10.24 (+4.92%)
MU   64.13 (+4.45%)
AMD   87.03 (+2.82%)
T   28.52 (+0.71%)
NIO   52.14 (+5.87%)
F   8.91 (+1.95%)
ACB   7.17 (+0.56%)
GILD   59.91 (-0.33%)
NFLX   483.39 (-0.99%)
BA   208.85 (+4.62%)
DIS   142.68 (+1.14%)
S&P 500   3,574.85 (+0.49%)
DOW   29,496.73 (+0.80%)
QQQ   290.39 (+0.00%)
AAPL   115.45 (-1.61%)
MSFT   209.88 (-0.24%)
FB   266.59 (-1.15%)
GOOGL   1,727.87 (-0.49%)
AMZN   3,092.90 (-0.21%)
TSLA   524.41 (+7.11%)
NVDA   525.72 (+0.42%)
BABA   270.13 (-0.23%)
CGC   24.08 (+1.52%)
GE   10.24 (+4.92%)
MU   64.13 (+4.45%)
AMD   87.03 (+2.82%)
T   28.52 (+0.71%)
NIO   52.14 (+5.87%)
F   8.91 (+1.95%)
ACB   7.17 (+0.56%)
GILD   59.91 (-0.33%)
NFLX   483.39 (-0.99%)
BA   208.85 (+4.62%)
DIS   142.68 (+1.14%)
Log in
NASDAQ:CERS

Cerus Stock Forecast, Price & News

$6.26
+0.03 (+0.48 %)
(As of 11/23/2020 10:50 AM ET)
Add
Compare
Today's Range
$6.20
Now: $6.26
$6.34
50-Day Range
$5.25
MA: $6.10
$6.82
52-Week Range
$2.71
Now: $6.26
$7.94
Volume14,356 shs
Average Volume1.78 million shs
Market Capitalization$1.05 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.22
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma that is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company has a collaboration with the National Trauma Institute to supply Intercept plasma for use in the plasma resuscitation without lung injury (PROpOLIs) clinical study. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.
Read More
Cerus logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.54 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:CERS
CUSIP15708510
Phone925-288-6000
Employees254

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$74.65 million
Book Value$0.65 per share

Profitability

Net Income$-71,240,000.00

Miscellaneous

Market Cap$1.05 billion
Next Earnings Date2/18/2021 (Estimated)
OptionableOptionable
$6.26
+0.03 (+0.48 %)
(As of 11/23/2020 10:50 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CERS News and Ratings via Email

Sign-up to receive the latest news and ratings for CERS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cerus (NASDAQ:CERS) Frequently Asked Questions

How has Cerus' stock price been impacted by COVID-19?

Cerus' stock was trading at $4.76 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CERS shares have increased by 31.5% and is now trading at $6.26.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Cerus?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cerus
.

What stocks does MarketBeat like better than Cerus?

Wall Street analysts have given Cerus a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cerus wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Cerus' next earnings date?

Cerus is scheduled to release its next quarterly earnings announcement on Thursday, February 18th 2021.
View our earnings forecast for Cerus
.

How were Cerus' earnings last quarter?

Cerus Co. (NASDAQ:CERS) announced its quarterly earnings data on Thursday, October, 29th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.12) by $0.04. Cerus had a negative net margin of 73.72% and a negative return on equity of 63.47%.
View Cerus' earnings history
.

What guidance has Cerus issued on next quarter's earnings?

Cerus updated its FY 2020 After-Hours earnings guidance on Thursday, October, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $89-91 million, compared to the consensus revenue estimate of $112.46 million.

What price target have analysts set for CERS?

4 equities research analysts have issued twelve-month price targets for Cerus' stock. Their forecasts range from $6.50 to $9.00. On average, they expect Cerus' stock price to reach $7.63 in the next twelve months. This suggests a possible upside of 21.8% from the stock's current price.
View analysts' price targets for Cerus
.

Who are some of Cerus' key competitors?

What other stocks do shareholders of Cerus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Pfizer (PFE), Immunomedics (IMMU), Exelixis (EXEL), Novavax (NVAX) and NVIDIA (NVDA).

Who are Cerus' key executives?

Cerus' management team includes the following people:
  • Mr. William M. Greenman, Pres, CEO & Director (Age 53, Pay $1.11M)
  • Dr. Laurence M. Corash, Co-Founder & Chief Scientific Officer (Age 76, Pay $646.48k)
  • Mr. Kevin D. Green, VP of Fin. & CFO (Age 48, Pay $608.68k)
  • Mr. Vivek K. Jayaraman, Chief Operating Officer (Age 45, Pay $671.02k)
  • Dr. Richard J. Benjamin, Chief Medical Officer (Age 60, Pay $620.21k)
  • Ms. Lori L. Roll, VP of Admin. & Corp. Sec.
  • Mr. Timothy J. Lee, Investor Relations Director
  • Ms. Chrystal N. Menard, Chief Legal Officer & Gen. Counsel (Age 49)
  • Lainie Corten, VP of Global Marketing
  • Ms. Carol M. Moore, Sr. VP of Regulatory Affairs, Quality & Clinical (Age 70)

What is Cerus' stock symbol?

Cerus trades on the NASDAQ under the ticker symbol "CERS."

Who are Cerus' major shareholders?

Cerus' stock is owned by many different institutional and retail investors. Top institutional investors include ARK Investment Management LLC (18.05%), BlackRock Inc. (8.13%), Nikko Asset Management Americas Inc. (5.84%), State Street Corp (2.72%), Paradigm Capital Management Inc. NY (1.02%) and Peregrine Capital Management LLC (0.95%). Company insiders that own Cerus stock include Carol Moore, Chrystal Menard, Daniel N Swisher Jr, Gail Schulze, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson, Timothy L Moore and William Mariner Greenman.
View institutional ownership trends for Cerus
.

Which institutional investors are selling Cerus stock?

CERS stock was sold by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., Squarepoint Ops LLC, Cubist Systematic Strategies LLC, BlackRock Inc., Victory Capital Management Inc., Lesa Sroufe & Co, Charles Schwab Investment Management Inc., and Wells Fargo & Company MN. Company insiders that have sold Cerus company stock in the last year include Carol Moore, Chrystal Menard, Daniel N Swisher Jr, Gail Schulze, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson, and William Mariner Greenman.
View insider buying and selling activity for Cerus
.

Which institutional investors are buying Cerus stock?

CERS stock was purchased by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, First Midwest Bank Trust Division, Morgan Stanley, Paradigm Capital Management Inc. NY, State Street Corp, Peregrine Capital Management LLC, Sei Investments Co., and Jackson Creek Investment Advisors LLC. Company insiders that have bought Cerus stock in the last two years include Timothy L Moore, and William Mariner Greenman.
View insider buying and selling activity for Cerus
.

How do I buy shares of Cerus?

Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cerus' stock price today?

One share of CERS stock can currently be purchased for approximately $6.26.

How big of a company is Cerus?

Cerus has a market capitalization of $1.05 billion and generates $74.65 million in revenue each year. The biotechnology company earns $-71,240,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. Cerus employs 254 workers across the globe.

What is Cerus' official website?

The official website for Cerus is www.cerus.com.

How can I contact Cerus?

Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The biotechnology company can be reached via phone at 925-288-6000 or via email at [email protected]

This page was last updated on 11/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.